Advertisement
10/26/2021

Currax welcomes new executive

As senior vice president of global marketing and strategic alliance management, Ed Cinca will lead worldwide commercial strategy for the entire Currax portfolio, including brand and generic medications.
Sandra Levy
Senior Editor
Sandra Levy profile picture

Currax, a specialty biopharmaceutical company of branded and generics products, is welcoming a new executive. Ed Cinca is joining as senior vice president, global marketing and strategic alliance management.

He will report to Currax's president and CEO, George Hampton.

Cinca will lead worldwide commercial strategy for the entire Currax portfolio with a priority focus on Contrave (naltrexone HCl/bupropion HCl), an oral weight-loss brand medication. He also will also oversee the company's global partnerships and strategic alliances.

"Obesity is the No. 1 preventable cause of death in the U.S. and has accelerated in prevalence as a result of the pandemic. More must be done to help patients suffering from this disease," said Currax president and CEO, George Hampton. "Currax is committed to this challenge and having Ed join our executive team increases our ability to support patients with obesity. His expertise in the category is unsurpassed and makes him a valuable addition to our leadership team."

[Read more: Retailers bolster specialty pharmacy capabilities as its role in the industry grows] 

Prior to joining Currax, Cinca most recently served as a Novo Nordisk leadership team member and vice president, head of cardiometabolic portfolio, where he led the launches of Ozempic, Rybelsus and Wegovy. He previously served in the roles of vice president, sales execution and operations, and senior brand director of Saxenda at NNI.

Cinca earned an MBA in marketing and finance from Fordham University and a Bachelor of Science in finance from Lehigh University. He is a board member of the New York/New Jersey American Diabetes Association and member of Steps Together, an organization that supports families impacted by medical crises.

"Currax is an industry leader in the obesity space," Cinca said. "I'm looking forward to applying my commercial experience in brand excellence and deep category expertise at such an exciting point in the company's growth trajectory. I'm excited to help advance Currax's mission to enhance the lives of patients by providing access to life-changing medications that treat diseases such as obesity."

Last month, Currax celebrated the official opening of its new headquarters and the future of Currax's business in the Nashville area.

Advertisement
Advertisement